Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa

NCT05322473 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

234

Enrollment

INDUSTRY

Sponsor class

Conditions

Hidradenitis Suppurativa

Interventions

DRUG: Sonelokimab (M1095)
DRUG: Adalimumab
OTHER: Placebo

Sponsor

MoonLake Immunotherapeutics AG